

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-102401-PIP01-26-M01

Scope of the Application

Active Substance(s)

ANDEXANET ALFA

Condition(s)

Treatment of factor Xa inhibitor associated haemorrhage, Prevention of factor Xa inhibitor associated haemorrhage

Pharmaceutical Form(s)

Powder for solution for infusion

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

AstraZeneca UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AstraZeneca UK Limited submitted to the licensing authority on 20/03/2026 12:15 GMT an application for a Modification

The procedure started on 13/04/2026 17:23 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102401-PIP01-26-M01

Of 22/04/2026 16:17 BST

On the adopted decision for ANDEXANET ALFA (MHRA-102401-PIP01-26-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for ANDEXANET ALFA, Powder for solution for infusion , INTRAVENOUS USE .

This decision is addressed to AstraZeneca UK Limited, 2 Pancras Square, 8th Floor, London, UNITED KINGDOM, N1C 4AG

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of factor Xa inhibitor associated haemorrhage. Prevention of factor Xa inhibitor associated haemorrhage.

2.2 Indication(s) targeted by the PIP:

For the reversal of anticoagulation due to direct and indirect factor Xa inhibitors in patients experiencing an acute major bleeding event. For the reversal of anticoagulation due to direct and indirect factor Xa inhibitors in patients requiring urgent surgery.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Powder for solution for infusion.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of appropriately sized vials to cover all the paediatric population
Non-Clinical Studies	0	Not applicable
Clinical Studies	3	Study 2 Open label, single dose trial to evaluate PK/PD of andexanet alfa in children from birth to less than 18 years of age, administered at the end of their treatment with enoxaparin Study 3 Open label, single dose trial to evaluate PK/PD of andexanet alfa in children from birth to less than 18 years of age, administered at the end of their treatment with rivaroxaban Study 4 Open label, single dose trial to evaluate PK/PD of andexanet alfa in children from birth to less than 18 years of age, administered at the end of their treatment with apixaban Study 5 removed from PIP during procedure MHRA-102401-PIP01-26-M01 Study 6 removed from PIP during procedure EMEA-001902-PIP01-15-M04.
Extrapolation, Modeling & Simulation Studies	1	Study 7 A population PK/PD model for the determination of andexanet dose and rate of infusion required for reversal of anticoagulation, for direct and indirect fXa inhibitors in paediatric populations
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/01/2032
Deferral of one or more studies contained in the paediatric investigation plan:	Yes